FDA logs more than 1,700 adverse event reports tied to compounded GLP-1 drugs
The tally gives patients a concrete measure of reported problems with compounded semaglutide and tirzepatide, which are not FDA-approved.
The Food and Drug Administration has received more than 1,700 reports of adverse events involving compounded semaglutide and tirzepatide, as of May 21, 2026, according to the agency's page on unapproved GLP-1 drugs used for weight loss [1].
The figure sits inside a longer list of safety and supply-chain concerns on that page. FDA points to import alerts meant to keep GLP-1 active pharmaceutical ingredients with quality problems out of the country; states its position that retatrutide and cagrilintide may not be used in compounding; cites dosing concerns with GLP-1 products; and warns that counterfeit versions of brand-name GLP-1 medicines are circulating [1].
Compounded semaglutide and tirzepatide are not FDA-approved. Pharmacies that make them under sections 503A and 503B of the federal food and drug law may qualify for exemptions from certain approval requirements, but those exemptions are conditioned on meeting statutory requirements, and the products do not go through the new drug application review that brand-name medicines do [1].
Details behind the 1,700-plus reports have not been disclosed. FDA has not published a breakdown by product, severity or outcome, and has not said whether it has determined that any individual case was caused by a compounded drug. Nor has the agency said how often it plans to refresh the number [1].
The disclosure lands during a renewed stretch of enforcement aimed at how compounded GLP-1s are promoted. In the week of June 15, 2026, FDA sent 25 warning letters to telehealth companies over marketing claims the agency considers false or misleading, and published a page for telehealth companies listing common compliance problems [1]. Earlier rounds include roughly 80 warning letters and 40 untitled letters in September 2025, 30 warning letters in March 2026, and 58 letters in late 2025 and early 2026 covering compounded GLP-1s plus other compounded products such as sildenafil and tadalafil [1].
The letters turn on what regulators call the net impression of advertising: whether a page or post, read as a whole, leaves a consumer thinking a compounded product is FDA-approved, FDA-reviewed or equal to an approved drug. FDA has objected to terms such as "generic," to "clinically proven" performance claims, to "FDA-approved" or "FDA-licensed" pharmacy sourcing language, and to branding that suggests a telehealth company does the compounding itself [1].
Michael Davis, the acting director of FDA's Center for Drug Evaluation and Research, wrote on X that patients "deserve to know what they're getting" and that compounded GLP-1 products "have not been proven safe, effective, or of consistent quality like FDA-approved drugs" [1].
Why it matters for patients
People taking a compounded version of semaglutide or tirzepatide are using a product that has not been through the same review for safety, effectiveness and manufacturing quality as Ozempic, Wegovy or Mounjaro [1]. The running total tells them that reported problems with these products are numerous enough for the agency to track and publish, while the absence of any breakdown means there is no public way to see which products or which kinds of harm are involved [1].
The marketing cases matter for a related reason. If promotional language leads someone to believe a compounded product is the same as an approved one, that belief can shape what they think they are buying. FDA's position is that such claims can make a product misbranded under federal law even when individual statements are literally true, because of the overall impression [1].
The warnings about counterfeit brand-name GLP-1s and about imported ingredients with quality problems point to risks in the supply chain that are separate from whether compounding itself is allowed [1].
What happens next
FDA has not announced a schedule for additional warning letters or said when it will next update the adverse event count [1]. The pattern so far has been quiet stretches followed by coordinated batches of letters — September 2025, March 2026 and June 2026 — rather than a steady stream, and the agency's new telehealth compliance page remains available to companies promoting compounded drugs [1]. Recent leadership changes at FDA, including the May 2026 dismissal of Commissioner Marty Makary, do not appear to have altered the agency's course on this issue [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.